Denali Therapeutics Inc. DNLI
20.96 USD +1.51 (+7.76%)
At closeNov 4, 2026, 5:03 PM EST
20.96 0.00 0.00%
After hours · Nov 4, 5:03 PM ET
19.75 Day range 22.19
13.75 52-week range 27.30
- YTD
- +26.95%
- 1 year
- +40.48%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 35.63 +70.0% upside
Now 20.96
- Target (low)
- 23.00
- Target (mean)
- 35.63
- Target (high)
- 42.00
Ratings (0m) 20 19 buy · 1 hold · 0 sell
- Strong buy2
- Buy17
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 20
- 1 month ago 20
- 2 months ago 20
- 3 months ago 20
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.5675 | -0.60 – -0.53 | -0.73 | +22.3% | 31.35M | 0.0% | 4 |
| Next quarter | -0.68333 | -0.82 – -0.58 | -0.69 | +1.0% | 30.33M | 0.0% | 3 |
| Current year | -2.05 | -2.56 – -1.59 | -2.97 | +30.9% | 52.50M | 0.0% | 5 |
| Next year | -2.36 | -3.20 – -1.70 | -2.05 | -15.2% | 143.51M | +173.3% | 16 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Nov 4, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Nov 4, 2026 | BTIG | Reiterated | Buy | Buy |
| Aug 25, 2026 | B. Riley Securities | Maintained | Buy | Buy |
| Aug 7, 2026 | UBS | Maintained | Buy | Buy |
| Jul 23, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Jul 16, 2026 | Deutsche Bank | Maintained | Buy | Buy |
| May 26, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 14, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 11, 2026 | BTIG | Reiterated | Buy | Buy |
| May 8, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Apr 22, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| Apr 7, 2026 | Baird | Maintained | Outperform | Outperform |
| Mar 26, 2026 | Morgan Stanley | Maintained | Overweight | Overweight |
| Mar 26, 2026 | Goldman Sachs | Maintained | Buy | Buy |
| Mar 26, 2026 | Stifel | Maintained | Buy | Buy |
| Mar 26, 2026 | Baird | Maintained | Outperform | Outperform |
| Mar 26, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 25, 2026 | BTIG | Maintained | Buy | Buy |
| Mar 2, 2026 | BTIG | Maintained | Buy | Buy |
| Feb 24, 2026 | Wolfe Research | Initiated | — | Peer Perform |
| Feb 6, 2026 | BTIG | Reiterated | Buy | Buy |
| Dec 11, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Dec 5, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Dec 5, 2025 | BTIG | Reiterated | Buy | Buy |
| Nov 4, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 8, 2025 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Aug 18, 2025 | Morgan Stanley | Maintained | Overweight | Overweight |
| May 19, 2025 | B of A Securities | Maintained | Buy | Buy |
| May 8, 2025 | Baird | Maintained | Outperform | Outperform |